← Back to Clinical Trials
Recruiting NCT04783441

NCT04783441 Use of CGM in Kidney Transplant Recipients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04783441
Status Recruiting
Phase
Sponsor University of California, Davis
Condition Kidney Transplant; Complications
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2021-06-29
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dexcom G6Dexcom G6 blinded sensor

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2021-06-29 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

Eligibility Criteria

Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding 9. Presence of clinically unstable cardiovascular disease 10. Active malignancy treatment

Contact & Investigator

Central Contact

Dahlia Zuidema, PharmD

✉ dmzuidema@ucdavis.edu

📞 916-734-4009

Principal Investigator

Ling Chen, MD

STUDY DIRECTOR

UCDavis Transplant Nephrology

Frequently Asked Questions

Who can join the NCT04783441 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04783441 currently recruiting?

Yes, NCT04783441 is actively recruiting participants. Contact the research team at dmzuidema@ucdavis.edu for enrollment information.

Where is the NCT04783441 trial being conducted?

This trial is being conducted at Sacramento, United States.

Who is sponsoring the NCT04783441 clinical trial?

NCT04783441 is sponsored by University of California, Davis. The principal investigator is Ling Chen, MD at UCDavis Transplant Nephrology. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology